Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 16Gynecologic 10Gastrointestinal 9Tumor-Agnostic 6Genitourinary 6Other solid neoplasm 4Head & Neck 2CNS 2Breast 2Sarcoma 1Other hematologic neoplasm 1NET 1Endocrine 1Dermatologic 1

Conditions

Glioblastoma 2Recurrence 1Oligodendroglioma 1Gliosarcoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 299Radiotherapy 219Bevacizumab 139Carboplatin 91Cyclophosphamide 88Etoposide 82Filgrastim 72Vincristine 69Irinotecan 69Magnetic Resonance Spectroscopy 65Cisplatin 59Radiation 58Radiosurgery 52Surgical Procedures, Operative 41Peripheral Blood Stem Cell Transplantation 40Topotecan 39Doxorubicin 39Lomustine 37Carmustine 36sargramostim 35Granulocyte Colony-Stimulating Factor 35Melphalan 34Nivolumab 32Chemotherapy, Adjuvant 32Radiotherapy, Intensity-Modulated 29Isotretinoin 29Everolimus 29Erlotinib Hydrochloride 27Thiotepa 25Vorinostat 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × nintedanib × CNS × Clear all
NCT01380782 2014-08-18

BIBF 1120 for Recurrent High-Grade Gliomas

Dana-Farber Cancer Institute

Phase 2 Completed
37 enrolled 11 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Oligodendroglioma, Recurrence, Gliosarcoma

NCT01251484 2012-10-04

BIBF 1120 in Recurrent Glioblastoma Multiforme

Rigshospitalet, Denmark

Phase 2 Completed
25 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡